Place des anticoagulants oraux directs dans la prise en charge de la maladie thromboembolique veineuse associée au cancer en 2020

Sanchez, 2019, Recommendations for best practice in the management of venous thromboembolic disease in adults. Long version, Rev Mal Respir, 8425, 30210 van der Wall, 2017, Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice, J Thromb Haemost JTH, 15, 74, 10.1111/jth.13563 Hellwig, 2013, Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?, Ann Pharmacother, 47, 1478, 10.1177/1060028013504741 Gouin-Thibault, 2017, Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin, J Thromb Haemost JTH, 15, 273, 10.1111/jth.13577 Mueck, 2013, Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects, Br J Clin Pharmacol, 76, 455, 10.1111/bcp.12075 Ueshima, 2017, Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation, Pharmacogenet Genomics, 27, 329, 10.1097/FPC.0000000000000294 Eadie, 2014, Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib, Clin Pharmacol Ther, 95, 294, 10.1038/clpt.2013.208 Riess, 2018, Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions, Crit Rev Oncol Hematol, 132, 169, 10.1016/j.critrevonc.2018.09.015 Chang, 2017, Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation, JAMA, 1250, 10.1001/jama.2017.13883 Moore, 2014, An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function, J Clin Pharmacol, 54, 1407, 10.1002/jcph.352 Douxfils, 2018, Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians, J Thromb Haemost, 16, 209, 10.1111/jth.13912 Vazquez, 2018, Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions, Blood, 132, 2230, 10.1182/blood-2018-06-848747 Bolek, 2019, The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation, Am J Ther, 26, e308, 10.1097/MJT.0000000000000599 Kubitza, 2006, Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects, J Clin Pharmacol, 46, 549, 10.1177/0091270006286904 Mueck, 2011, Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention, Clin Pharmacokinet, 50, 675, 10.2165/11595320-000000000-00000 Gelosa, 2018, Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs), Pharmacol Res, 135, 60, 10.1016/j.phrs.2018.07.016 Giugliano, 2013, Edoxaban versus Warfarin in Patients with Atrial Fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 Raskob, 2018, Edoxaban for Cancer-Associa ted Veno us Thromboembolism, N Engl J Med, 379, 95 Khorana, 2018, Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH, J Thromb Haemost, 16, 1891, 10.1111/jth.14219 Young, 2018, Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D), J Clin Oncol, 2017, 10.1200/JCO.2018.78.8034 Li, 2019, Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis, Thromb Res, 173, 158, 10.1016/j.thromres.2018.02.144 Storrar, 2019, Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens, Br J Haematol, 185, 142, 10.1111/bjh.15392 Kraaijpoel, 2018, Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: results from the Hokusai VTE Cancer Study, Thromb Haemost, 118, 1439, 10.1055/s-0038-1667001 Carrier, 2019, Apixaban to Prevent Venous Thromboembolism in Patients with Cancer, N Engl J Med, 380, 711, 10.1056/NEJMoa1814468 Key, 2020, Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update, J Clin Oncol, 38, 496, 10.1200/JCO.19.01461 Farge, 2019, 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, Lancet Oncol, 20, e566, 10.1016/S1470-2045(19)30336-5 Thompson, 2016, Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study, ABr J Haematol, 175, 462, 10.1111/bjh.14324 Trone, 2018, Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events-a meta-analysis, Ann Oncol, 29, 803, 10.1093/annonc/mdy035 Bellesoeur, 2018, Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences, Crit Rev Oncol Hematol, 129, 102, 10.1016/j.critrevonc.2018.06.015 Steffel, 2018, The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur Heart J, 39, 1330, 10.1093/eurheartj/ehy136